|Bid||0.00 x 900|
|Ask||0.00 x 1800|
|Day's Range||4.44 - 4.71|
|52 Week Range||0.72 - 6.04|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.17|
In its latest look at the financials of these publicly traded companies, Triangle Business Journal dove deeper into the data to see how these companies fall in the various regions of the state and how those areas stack up as of July 31, 2018 – and how these companies compare to last year.
Earnings season is in full swing, and companies are busy reporting their performance for the second quarter of the fiscal year. The same is true for Research Triangle Park’s biotech companies, BioDelivery Sciences (Nasdaq: BDSI), TransEnterix (Amex: TRXC) and Dova Pharmaceuticals (Nasdaq: DOVA) all announced their financial results during after-market hours in recent days.
TransEnterix (TRXC) reported its second-quarter earnings on Tuesday, August 7, before the market opened. TransEnterix generated second-quarter revenues of $6.4 million compared to $1.6 million in the second quarter of 2017.
TransEnterix (NYSE: TRXC) is seeing its revenue climb on more sales following its initial U.S. Food and Drug Administration clearance late last year, although the company is still showing losses overall. On Tuesday, the Research Triangle Park-based surgical robot maker reported revenue of $6.4 million in the second quarter of 2018, compared to revenue of just $1.6 million in the second quarter of last year. TransEnterix reported a net loss of $34.2 million, or $0.17 per share, for the second quarter of 2018, compared to a net loss of $14.7 million, or $0.11 per share, for the second quarter of last year.
TransEnterix (TRXC) delivered earnings and revenue surprises of 0.00% and 3.05%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Morrisville, North Carolina-based company said it had a loss of 17 cents per share. Losses, adjusted for non-recurring costs and amortization costs, were 6 cents per share. The maker of surgical robots ...
TransEnterix, Inc. , a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the second quarter 2018.
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / TransEnterix, Inc. (NYSE American: TRXC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...
TransEnterix, Inc. announced today that it plans to release second quarter 2018 financial and operating results before the market opens on Tuesday, August 7, 2018.
In June, TransEnterix (TRXC) submitted its 510(k) filing to the FDA for approval of additional Senhance system instruments. In the United States, Senhance has been approved by the FDA for laparoscopic gynecology, colorectal, inguinal hernia, and cholecystectomy surgical procedures. In May, the FDA cleared TransEnterix’s 510(k) for expansion of the use of Senhance for laparoscopic inguinal hernia and cholecystectomy surgery.
In the first quarter, TransEnterix (TRXC) generated revenues of $4.8 million compared to $1.9 million in Q1 2017, reflecting a 145% year-over-year growth. It reported cost of revenue of $2.6 million compared to $1.3 million in the first quarter of 2017. Wall Street analysts estimate that TransEnterix will generate revenues of $5.66 million in the second quarter. On July 2, in TransEnterix’s corporate update, it noted that its second-quarter revenues would be $6 million–$6.3 million.
On July 12, TransEnterix (TRXC) stock closed at $4.44, reflecting a 2.78% growth from its prior day’s close of $4.32. On July 11, the stock rose 8.54% from its close of $3.98 on July 10. TransEnterix is focused on the development of medical devices that use robotics to improve minimally invasive surgery. On June 25, TransEnterix announced its addition to the Russell 2000 Index, effective June 25. Russell US indexes are used extensively by investors, institutional investors, and investment managers to create a benchmark for making investment strategies.
TransEnterix Inc (NYSE: TRXC), a robotic medical device company aiming to digitize the interface between surgeons and patients in laparoscopy, surged an impressive 125.9% in the first half of 2018, owing to a multitude of bullish factors. The company seeks to assist qualified laparoscopists to perform complex surgeries with the assistance of robotic technology. Here we use TipRanks data to take a closer look at what Wall Street's top analysts see in store for this volatile stock.
LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on TRXC sign up now at www.wallstequities.com/registration. WallStEquities.com takes a close look at four Medical Instruments and Supplies stocks, particularly, Tandem Diabetes Care Inc. (NASDAQ: TNDM), The Cooper Cos. Inc. (NYSE: COO), TransEnterix Inc. (NYSE American: TRXC), and Waters Corp. (NYSE: WAT).
From Iqvia to Red Hat, insiders at Triangle companies have raked in millions in the first half of 2018 by selling shares, SEC filings show.
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today provided a corporate update, including the announcement of the sale of an additional Senhance system as well as preliminary unaudited revenue for the second quarter ended June 30, 2018.
On May 29, the FDA approved TransEnterix’s Senhance Surgical System in laparoscopic inguinal hernia and laparoscopic gallbladder removal indications. The sudden drop in TransEnterix’s share price is due to BTIG analyst Sean Lavin downgrading the stock to “neutral.” Also, the company withdrew its previous target price, which impacted overall investor sentiment.
Transenterix Inc (NYSE: TRXC) shares have spiked 50 percent in the last week, 71 percent in the last month and 734 percent in the last year. By Lavin’s assessment, the pop in price reflects no fundamental improvements or risk alleviation around commercialization.